Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Irving

Showing results (261-270 of 321) with videos related to

Pageof 33
Sort By:
Alimentary Pharmacology & Therapeutics|June 1, 2019
The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosisAli Jibran Mecci, Polychronis Kemos, Clifford Leen, et al.
Vox Sanguinis|February 29, 2024
Blood donation screening for hepatitis B virus core antibodies: The importance of confirmatory testing and initial implication for rare blood donor groupsMichael X Fu, Jennifer Ingram, Courtney Roberts, et al.
Clinical and Experimental Immunology|December 21, 2006
Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complexK S Brown, M J Keogh, N Tagiuri, et al.
Journal of Viral Hepatitis|July 19, 2008
Diagnosis of acute hepatitis C virus infection and estimated incidence in low- and high-risk English populationsL J Brant, M E Ramsay, M A Balogun, et al.
JHEP Reports : Innovation in Hepatology|June 7, 2023
PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver diseaseMette J Nielsen, Grace E Dolman, Rebecca Harris, et al.
Journal of Viral Hepatitis|January 21, 2014
The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapyM Backx, A Lewszuk, J R White, et al.
Journal of Viral Hepatitis|April 14, 2006
Clinical pathways for patients with newly diagnosed hepatitis C - what actually happensW L Irving, S Smith, R Cater, et al.
The Journal of Infectious Diseases|September 23, 2021
The Impact of Real-Time Whole-Genome Sequencing in Controlling Healthcare-Associated SARS-CoV-2 OutbreaksRodric V Francis, Harriet Billam, Mitch Clarke, et al.
Journal of Hepatology|October 30, 2001
Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre studyS Caronia, M F Bassendine, R Barry, et al.
Journal of Medical Virology|October 5, 2023
Ultrasensitive PCR system for HBV DNA detection: Risk stratification for occult hepatitis B virus infection in English blood donorsMichael X Fu, Peter Simmonds, Julien Andreani, et al.
Pageof 33

Showing results (261-270 of 321) with videos related to

Sort By:
Pageof 33
Alimentary Pharmacology & Therapeutics|June 1, 2019
The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosisAli Jibran Mecci, Polychronis Kemos, Clifford Leen, et al.
Vox Sanguinis|February 29, 2024
Blood donation screening for hepatitis B virus core antibodies: The importance of confirmatory testing and initial implication for rare blood donor groupsMichael X Fu, Jennifer Ingram, Courtney Roberts, et al.
Clinical and Experimental Immunology|December 21, 2006
Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complexK S Brown, M J Keogh, N Tagiuri, et al.
Journal of Viral Hepatitis|July 19, 2008
Diagnosis of acute hepatitis C virus infection and estimated incidence in low- and high-risk English populationsL J Brant, M E Ramsay, M A Balogun, et al.
JHEP Reports : Innovation in Hepatology|June 7, 2023
PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver diseaseMette J Nielsen, Grace E Dolman, Rebecca Harris, et al.
Journal of Viral Hepatitis|January 21, 2014
The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapyM Backx, A Lewszuk, J R White, et al.
Journal of Viral Hepatitis|April 14, 2006
Clinical pathways for patients with newly diagnosed hepatitis C - what actually happensW L Irving, S Smith, R Cater, et al.
The Journal of Infectious Diseases|September 23, 2021
The Impact of Real-Time Whole-Genome Sequencing in Controlling Healthcare-Associated SARS-CoV-2 OutbreaksRodric V Francis, Harriet Billam, Mitch Clarke, et al.
Journal of Hepatology|October 30, 2001
Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre studyS Caronia, M F Bassendine, R Barry, et al.
Journal of Medical Virology|October 5, 2023
Ultrasensitive PCR system for HBV DNA detection: Risk stratification for occult hepatitis B virus infection in English blood donorsMichael X Fu, Peter Simmonds, Julien Andreani, et al.
Pageof 33